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ABSTRACT
Objectives: To determine whether intravaginal clindamycin cream reduces the incidence of abnor-
mal pregnancy outcome in women with abnormal vaginal microbial flora graded as intermediate or
BV and to investigate the effect of the antibiotic on vaginal microbial flora.
Methods: A prospective cohort study of pregnant women in an antenatal clinic of a district
general hospital. The subjects were 268 women who had abnormal vaginal microbial flora at first
clinic visit by examination of a Gram-stained vaginal smear and 34 women with a normal vaginal
flora. Two hundred and thirty-seven women were evaluable. Women with abnormal Gram-stained
smears (graded as II or III) on clinic recall were randomised to receive treatment (intravaginal
clindamycin cream) or placebo and followed to assess outcome of pregnancy, vaginal flora, and
detection of Mycoplasma hominis and Ureaplasma urealyticum after treatment.
Results: Abnormal outcomes of pregnancy were not significantly different in treated and placebo
groups by Chi square (P 0.2). However, women with grade III flora responded better to clinda-
mycin than women with grade II flora by numbers of abnormal outcomes (P 0.03) and return to
normal vaginal flora (P 0.01) (logistic regression analysis model). This may be due to differences
in vaginal bacterial species in these grades. Women whose abnormal vaginal flora had spontane-
ously returned to normal on follow-up and were therefore not treated (revertants) had as many
abnormal outcomes as placebos suggesting that damage by abnormal bacterial species occurred
early in pregnancy.
Conclusions: Gram-stain screening distinguishing grade II from grade III flora may be helpful
in prescribing treatment other than clindamycin for women with grade II flora. Earlier diagnosis
and treatment may be more effective in preventing an abnormal outcome, possibly as soon as
pregnancy is diagnosed or even offered as a pre-conception screen. Infect. Dis. Obstet. Gynecol.
8:158-165, 2000. (C) 2000 Wiley-Liss, Inc.
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reterm delivery is the most important cause of
perinatal mortality and morbidity. Abnormal
microbial colonisation of the vagina with a mixture
of aerobic, anaerobic, and microaerophilic bacteria,
as seen in bacterial vaginosis (BV), is considered to
be an important indicator of women at risk. 1-4 In a
recent study of pregnant women by our group,
those who had BV at their first antenatal clinic at-
tendance were five times more likely to have a
preterm delivery or second trimester spontaneous
abortion than women who did not have BV.s There
also was a separate association of grade II (inter-
mediate) flora with late miscarriage,s The logical
consequence of this was to determine whether an-
tibiotic treatment is effective in reducing the inci-
dence of an abnormal outcome of pregnancy in
women with BV and also in women with abnormal
flora graded as II and to determine the effect of the
antibiotic on the vaginal microbial flora. The re-
suits of such a study are presented here.
SUBJECTS AND METHODS
This study was part of a multicenter double-blind
placebo-controlled trial to be reported at a later
date. The study design for the multicenter study
(with a population of 500 subjects: 250 in eacharm)
provided a power of at least 80% for detecting a
10% difference between groups at a significance
level of 5%; that is an abnormal event incidence of
8% in the clindamycin group compared with an
expected incidence of 18% in the placebo group.
This is based on previous data (R. Lamont, per-
sonal communication).
This paper describes the portion of the study
completed at Northwick Park Hospital, where ad-
ditional detailed microbiological findings were car-
ried out together with a study of the revertant
group and additional analyses that were not under-
taken at the other centres taking part in the study.
Women between 12 and 16 weeks of gestation
making their first antenatal visit to Northwick Park
Hospital were examined for evidence of abnormal
vaginal flora. The prevalence of abnormal vaginal
flora in the population of women attending this
clinic had been found previously to be 15%.s The
diagnosis of abnormal vaginal flora was based on
microscopic examination of a Gram-stained smear
of vaginal secretion. Three categories were
recognised as previously described:s grade I- nor-
mal, comprising predominantly lactobacillus mor-
photypes; grade II- abnormal (intermediate), in
which lactobacilli are reduced and mixed with
other bacterial morphotypes; grade III- abnormal
(BV) with few or no lactobacillus morphotypes and
greatly increased numbers of other morphotypes.
The Gram-stained slides were examined after the
clinic session. Women diagnosed as having abnor-
mal flora (grade II or grade III) were asked to re-
turn to the clinic within three weeks to one month
of their initial examination at which time they were
examined again for evidence of abnormal flora by
the same Gram-stain procedure. Women whose
Gram-stained smear was still abnormal (grade II or
grade III) were randomised to receive active treat-
ment [intravaginal clindamycin cream (2%) (Phar-
macia & Upjohn Ltd.)], or placebo. Treatments
were assigned using a computerised randomised-
block procedure with a block size of 10. Randomi-
sation was effected by means of a computer-
generated random code list with patients allocated
to the lowest available code number from the list.
Treatment was given at between 16 and 20 weeks
of gestation. Informed written consent to take part
was obtained from the volunteers, the study having
received approval by the institutional Ethics Com-
mittee. The following swab specimens were ob-
tained from the women and tested as indicated: an
endocervical swab for the detection of Chlamydia
trachomatis by an enzyme immunoassay (Micro-
Trak, Syva), an endocervical swab for the isolation
of Neisseria gonorrhoeae, and a high vaginal swab for
the detection of motile Trichomonas vaginalis by mi-
croscopic examination of a saline wet-mount prepa-
ration. The methods have been described fully
elsewhere.6 Women were excluded from the study
if there was any evidence of sexually transmitted
disease. Further high vaginal swabs were taken to
be examined for aerobic, anaerobic, and microaero-
philic species including Mycoplasma hominis and
Ureaplasma urealyticum. Details of the vaginal mi-
crobiology have been reported previously.
6
One hundred and fourteen women were asked
to apply 5 grams of clindamycin cream (2%) and
113 women were asked to apply a placebo cream
intra-vaginally at bedtime on three consecutive
days following diagnosis. The composition of treat-
ment and placebo creams was identical, except that
the placebo cream did not contain clindamycin.
The latter accounted for a small proportion of the
overall formulation. The three-day regimen was
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chosen based on a previous clinical study by Phar-
macia Upjohn Ltd., showing therapeutic eq.uiva-
lence to seven-day topical clindamycin for treat-
ment of BV. This regimen has been approved in
several countries (R. Lamont, personal communi-
cation). The women were followed-up with three
further outpatient visits at week 3 (20-24 days after
entering the study), week 6, and finally at 28-34
weeks of gestation. At each visit, a Gram stain
evaluation of vaginal secretion was made. If the
Gram-stained smear was still abnormal at week
three, a seven-day course of further treatment was
offered. This could be either active treatment or
placebo depending on initial randomisation. Com-
pliance with the study was assessed by asking pa-
tients to return tubes of cream after use, whether
empty or not, at the next follow up visit. At the
final visit a follow-up swab sample was. taken for
detection of M. hominis and U. urealyticum. A final
assessment of each woman was made 24 hours after
delivery (or 48 hours after miscarriage) to provide a
pregnancy outcome report which included a record
of abnormal events and a neonate report. In this
study as opposed to the whole multicenter trial,
two further groups of women attending their first
antenatal clinic visit at Northwick Park Hospital
also were studied in terms of their vaginal microbial
flora, previous obstetric history, and outcome of
pregnancy. These were, firstly, 41 women who
were described as ’revertants’ because they had
had an abnormal Gram stain result on their first
visit but on returning to the clinic their abnormal
vaginal flora was found to have resolved spontane-
ously and the Gram stain scored as grade I. The
second group of 34 women was not randomised,
but had normal grade flora on initial and subse-
quent screening and clinically had no evidence of
BV. The full vaginal microbiology of both groups of
women has been described previously.6
Statistical Method
A one-way analysis of variance with the Bonferroni
multiple comparison procedure was carried out to
compare the mean ages in the four groups; abnor-
mal flora (treated and placebo), revertants, and
those with normal flora. A logistic regression model
was calculated to determine whether an abnormal
outcome of pregnancy could be predicted from ini-
tial grade of vaginal flora and treatment. This
analysis also was performed to determine whether
the final grade of vaginal flora could be predicted
from the initial grade and treatment. All other as-
sociations were tested for statistical significance us-
ing the Chi squared test with a P value of less than
0.05 indicating a statistically significant difference.
RESULTS
Description of Cohort
Two hundred and sixty-eight women found to
have an abnormal vaginal flora at their first ante-
natal appointment were asked to return to the
clinic for follow-up. On return, 41 (15%) women
had resolved their abnormal flora spontaneously
(revertant group). Of the remaining 227 women
with abnormal flora, 114 received clindamycin and
113 placebo. In addition, there were 34 women
with a normal vaginal flora on initial screening with
no history of BV.
There were 31 exclusions from the treatment
group and 28 from the placebo group. These were:
no study data (3), no obstetric/gynaecological data
(12), failure to use cream (5), C. trachomatis positive
(5), T. vaginalis positive (1), no follow-up data (5),
no follow-up Gram-stained smear (28). Thus there
were 83 women who were evaluable in the clinda-
mycin group and 85 in the placebo group. In addi-
tion, 4 revertants and 2 with normal flora were ex-
cluded leaving a total of 237 evaluable women.
The demographic data of the antenatal popula-
tion are shown in Table 1. There was no significant
difference between the women with abnormal flora
given treatment and placebo with respect to age,
weight, height, race, and gestational age at base-
line, history of smoking, alcohol, or substance
abuse. Similarly, there was no significant difference
between the groups with respect to past medical
history, gravidity, parity, or other features of past
obstetric history, or history of sexually transmitted
infections. Women with normal vaginal flora were
significantly older than those in each of the other
three groups (P < 0.02); there was no significant
difference between the other three groups in terms
of age. The demographic characteristics of the
group of women with abnormal vaginal flora who
were treated were not significantly different from
those who were given the placebo (P > 0.05). There
was a larger proportion of women of Afro-
Caribbean origin in the group of women with ab-
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TABLE I. Demographic data for women in the clindamycin trial, for the revertant group, and for healthy
pregnant women with normal flora
Women with abnormal flora
Treated with Women with
clindamycin Given placebo Revertants normal flora
Number of women 83 85 37 32
Mean age + s.d. 30 + 4.5 29 + 5 29 + 6 33 + 5
Ethnic origin known 82 83 37 27
Caucasian 45 (55%) 41 (49%) 22 (59%) 17 (63%)
Asian 17 (21%) 19 (23%) (30%) 6 (22%)
Afro-Caribbean 18 (22%) 21 (25%) 3 (8%) 3 (I 5%)
Other 2 (2%) 2 (2%) (3%) (4%)
Smoker known 79 82 36 32
No 56 (71%) 58 (71%) 27 (75%) 30 (94%)
Yes 20 (25%) 19 (23%) 5 (I 4%) (3%)
Exsmoker 3 (4%) 5 (6%) 4 (11%) (3%)
History of abnormal pregnancy 23 (28%) 26 (30%) 14 (38%) 16 (50%)
Spontaneous abortion 19 24 14 14
Preterm delivery 4 4 2 2
aSome of the women will have had more than one previous abnormal pregnancy.
normal flora than in the revertants (P 0.04). When
combining the data from all women with abnormal
flora at first visit (that is, treated, placebo, and re-
vertant groups) there was then a significantly
higher proportion of smokers in this combined
group than in those with normal vaginal flora (P
0.03). Treated, placebo, and revertant groups had
similar incidences of a history of abnormal preg-
nancy in terms of previous spontaneous abortion
and/or preterm delivery. The group with normal
vaginal flora showed a surprisingly higher inci-
dence (P 0.03).
A normal distribution of blood groups was found
among the group ofwomen who had abnormal flora
and also among the sub-groups of women with an
abnormal outcome of this pregnancy (data not
shown).
Outcome of Pregnancy
The outcome of pregnancy in the four groups is
shown in Table 2. When women with an abnormal
flora (i.e., grade II and grade III) were considered
together, the proportion of women with an abnor-
mal outcome of pregnancy in the treated group
(19%) was not significantly different from that in
the placebo group (27%) (P 0.2), nor in the re-
vertant group (24%). After combining all women
with abnormal flora on first visit, i.e., treated, pla-
cebo, and revertant groups, and comparing this
combined group with the women who had a normal
vaginal flora, the proportion of women in the corn-
bined group with an abnormal outcome of preg-
nancy (23%) was very much greater than the pro-
portion in the group with normal flora (3%) (P
0.008). An interesting finding was that the propor-
tion of women in the revertant group (abnormal
flora at first visit which then reverted spontane-
ously to normal by the time they were recalled to
clinic) who had an abnormal outcome of pregnancy
(24%) was similar to that in the placebo group with
abnormal flora who were not treated (27%).
The data were then analysed further in terms of
grade of abnormal flora in relation to abnormal out-
come (Table 3). There was no significant differ-
ence in numbers of abnormal outcomes between
treated women with grade II flora (28%) and
treated women with grade III flora (17%) (P 0.3)
and similarly no significant difference in the pla-
cebo group (P 0.2). There was no significant dif-
ference in numbers of abnormal outcomes in
women with grade II flora who were treated (28%)
and those who were not (16%) (P 0.4). The dif-
ference between the treated (17%) and placebo
group (30%) of women with grade III flora ap-
proached significance (P 0.072). However, a lo-
gistic regression model demonstrated a significant
interaction between the initial grade of vaginal
flora and treatment (P 0.03) (i.e., women with
grade III flora responded significantly better to
clindamycin treatment than did women with grade
II flora in terms of the outcome of pregnancy).
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TABLE 2. Outcome of pregnancy
Women with abnormal flora
Treated with
clindamycin Given placebo Revertants
Women with
normal flora
Number of women 83 85 37 32
Pregnancy loss <22 weeks 3 3 0 0
Fetal death 2 0 0
Preterm birth
34-37 weeks 5 4 0 0
<34 weeks 3 5 0
Low birthweight
.5-2.5 kg 5 0 2
<1.5 kg 2 3 0
Infections of
Mother 5 6 6 0
Baby 3 3 2
Total number women with abnormal
outcome of pregnancy 16 (I 9%) 23 (27%) 9 (24%) (3%)
TABLE 3. Effect of clindamycin on outcome of pregnancy in relation to grade of vaginal flora
Grade of vaginal flora (at beginning of study)
II (37)
No. (%) women with
abnormal outcome
No. women of pregnancy No. women
No. (%) women with
abnormal outcome
of pregnancy
Women treated with clindamycin (83)
Women given placebo (85)
18 5 (28%) 65 (I 7%)
19 3 (I 6%) 66 20 (30%)
Vaginal Microbiology
The effect of clindamycin on the vaginal microbial
flora, as assessed by Gram-stain examination, is
shown in Table 4. It is clear that while clindamycin
was effective in reducing the proportion of women
with abnormal flora in the group whose flora graded
initially as III (P < 0.001), it did not significantly
affect that proportion of women whose flora was
graded initially as II (P 0.6). The data were then
analysed by a logistic regression model to predict
final grade of vaginal flora from initial grade and
treatment. There was a significant interaction be-
tween the initial grade of vaginal flora and treat-
ment (P 0.01) (i.e., women whose flora initially
graded as III and were treated, were significantly
more likely to have their flora return to normal than
those who were graded as II and were treated).
There was still a substantial proportion of
women with grade III flora, that is 16 of 65 (25%),
treated with clindamycin whose flora remained ab-
normal at the end of the study. In view of this the
data were analysed to determine if the vaginal mi-
crobial flora (at the beginning of the study) of
women whose Gram-stained smears remained ab-
normal throughout pregnancy (in both treated and
placebo groups) was different from that of women
whose Gram-stained smears returned to normal. It
appears that anaerobic Gram-negative rods were
underrepresented in the group of women whose
flora remained abnormal after clindamycin treat-
ment (P 0.02), whereas the distribution of other
bacterial species was similar throughout the groups
(data not shown).
Of the women with grade II flora for whom de-
tailed microbiology was available, 6 of 15 (40%) in
the treated group and 7 of 12 (58%) in the placebo
group had flora that remained as grade II. Of these,
two in the treated group and one in the placebo
group had group B streptococcal infection after de-
livery (data not shown).
Baseline swab samples (taken at recruitment to
the trial) and follow-up swab samples for the de-
tection of M. hominis and U. urealyticum were taken
from 78 women (42 in the treated and 36 in the
placebo group). Detection and cure rates for both
these organisms are shown in Table 5.
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TABLE 4. Effect of clindamycin on vaginal flora as assessed by Gram stain at end of study
Grade of vaginal flora (at beginning of study)
II (37)
No. (%) women with No. (%) women with
abnormal flora at abnormal flora at
No. women end of study No. women end of study
Women treated with clindamycin (83)
Women given placebo (85)
18 9 (50%) 65 16 (25%)
19 II (58%) 66 51 (77%)
TABLE 5. Detection of Mycoplasma hominis and
Ureaplasma urealyticum from women at recruitment
to the study and at follow up
Treated Women given
women (42) placebo (36)
Mycoplasma hominis
Before treatmet 15 (36%) 17 (47%)
Follow-up 2 (5%) 13 (36%)
Cure rate 13/I 5 (87%) 4/I 7 (23%)
Ureaplasma urealyticum
Before treatment 25 (60%) 26 (72%)
Follow-up 15 (35%) 21 (58%)
Cure rate 10/25 (40%) 5/26 (I 9%)
The data were analysed further to determine if
the demographic characteristics of the group of
treated women whose Gram-stained smear, re-
mained abnormal at the end of the study were dif-
ferent from those of the group of treated women
whose Gram-stained smear was normal at the end
of the study. This also was undertaken on data
from the placebo group (data not shown). It ap-
pears that smokers in the treated group were
slightly but not significantly more likely to have an
abnormal Gram-stained smear at the end of the
study than were non-smokers. The proportion of
Afro-Caribbean women in the four groups was
similar, indicating that although women of this eth-
nic group have a higher incidence of BV (Table 1),
they respond to treatment or placebo in a similar
way to women in the other ethnic groups. Women
with an abnormal Gram-stained smear at the end of
treatment were more likely to have a history of
abnormal pregnancy and an abnormal outcome in
the current pregnancy than those whose Gram-
stained smear returned to normal. However, none
of the differences was significant.
DISCUSSION
A higher incidence of Afro-Caribbean women and
of smokers was found in women who had abnormal
vaginal flora. This is consistent with previous data
obtained for a similar population of womens and is
in agreement with the findings of other workers. 7,8
It recently has been suggested that ethnic differ-
ences can be accounted for by differences in geni-
tal hygiene behaviour as an association has been
found between bacterial vaginosis, use of bubble
bath, or antiseptic solutions, or douching and eth-
nicity (black Caribbean).
9 A link between certain
blood group antigens and susceptibility to some
infectious diseases has been proposed.1 However,
there was no indication from the results of this
study that women of a particular blood group were
more likely to have an abnormal vaginal flora.
The proportion of women who had an abnormal
outcome of pregnancy was very high. Overall, the
women attending the antenatal clinic at Northwick
Park Hospital represent a low risk population with
less than 9% of the population as a whole having a
preterm birth,s However, in the previous studys of
women having abnormal vaginal flora, this propor-
tion rose to 16%. Thus we feel that the women
with abnormal vaginal flora represent a proportion
of the population most at risk. The proportion of
women who had an abnormal outcome of preg-
nancy after treatment with clindamycin was not
significantly different from the proportion who had
an abnormal outcome after being given the pla-
cebo, if women with grade II and grade III flora
were considered together. However, if considered
separately, women with grade III flora responded
to clindamycin treatment significantly better than
did women with grade II flora, in terms of outcome
of pregnancy and return to normal flora. These
findings suggest that there are important differ-
ences in the vaginal flora of pregnant women
graded as II and III and that careful distinction
between the two is essential.
A further important finding was that the propor-
tion ofwomen in the "revertant" group who had an
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abnormal outcome (24%) was similar to that of
women in the placebo group (27%). This suggests
that damage may have been caused by the various
bacterial species in the genital tract early in preg-
nancy before a reversion of the vaginal flora to nor-
mality. This is consistent with the findings of
Gratacos et al., 11 who also demonstrated that the
diagnosis of BV at any point during pregnancy was
associated with an increased risk of perinatal com-
plications even if the abnormal flora was found to
resolve spontaneously in examinations later in
pregnancy. This invites a determination of the
value of treatment earlier in pregnancy.
Subsequent to the demonstration by several
groups of investigators of the association between
BV and preterm birth, 1-s there have been several
clinical trials to determine the effect of treating BV
on the outcome of pregnancy. For example, the
results of three separate studies lz-14 showed that
topical intravaginal clindamycin was effective in
eradicating an abnormal vaginal flora in both non-
pregnantlz and pregnant women. 13,14 However, it
did not reduce the risks of perinatal morbidity or
preterm delivery. 13,4 In these studies, as in ours,
treatment was given at 16-27 weeks of gestation.
Oral metronidazolc and erythromycin given at 23
weeks of gestation both effectively reduced the
prevalence of BV in pregnant women and reduced
the rate of pretcrm delivery,
is Similarly, oral clin-
damycin also was effective in reducing the rate of
preterm delivery.
16 Although topical therapy may
be effective in eradicating local abnormal vaginal
flora, it may not affect bacteria colonising the upper
genital tract and thus oral therapy may be necessary
to prevent the adverse effects of bacteria and bac-
terial products. A recent intervention study using
oral metronidazole to prevent preterm delivery in
pregnant women with asymptomatic bacterial vag-
inosis has failed to demonstrate a reduction in pre-
term delivery in the treatment group. 17 However, it
appears that in some cases up to eight weeks
elapsed between diagnosis of BV and randomisa-
tion. During this period, ascending colonisation of
the upper genital tract may have occurred in a pro-
portion of these women causing damage irrevers-
ible by subsequent treatment.
In our study, topical clindamycin contributed to
the flora returning to normal in women with grade
III flora, but women who had Gram-stained smears
of grade II at the beginning of the study were less
likely to respond to treatment. The full microbiol-
ogy of the different Gram-stain categories has been
described before6 and it has been shown that the
flora can switch spontaneously from an abnormal to
a normal state. The data from our previous study
6
suggest that there is a trend for certain bacterial
species to be expressed in large numbers in a defi-
nite order with anaerobic Gram-negative rods and
anaerobic Gram-positive cocci increasing in num-
bers at the end of grade II and the beginning of
grade III, and Gardnerella vagina/is and M. hominis
organisms occurring in large numbers only in the
very late stages. As all these organisms are very
sensitive to clindamycin, it seems likely that
women with grade III flora will respond well to
clindamycin (in terms of a return to normal flora).
This was shown in this study both with regard to
the results of Gram-staining vaginal smears at the
end of study and to the detection rate of 31. hominis
after treatment. Interestingly, U. urealyticum organ-
isms were little affected by treatment, which is not
surprising since they are not sensitive to therapeu-
tic levels of clindamycin. It is a moot point whether
their elimination would have improved further the
outcome of pregnancy, particularly as 42% of the
women with normal vaginal flora in our previous
study
6 were positive for U. urealyticum, with no ab-
normal outcome of pregnancy.
The results of our previous study6 showed that
women with grade II flora had a higher incidence
of beta-haemolytic Streptococcus spp. which are rela-
tively much less sensitive to clindamycin. Further-
more, women whose Gram-stained smear remained
abnormal were less likely to be carrying anaerobic
Gram-negative rods at the beginning of the study.
Thus, the vaginal microbial flora of these women
was less responsive to clindamycin therapy. In the
other clinical studies referred to,e-7 no distinction
was made between women with flora graded as II
or III and therefore it was not possible to identify
the sub-group of women potentially unresponsive
to clindamycin.
CONCLUSIONS
The results of this study have demonstrated for the
first time that a sub-group of women exists within
those who have an abnormal vaginal flora and that
this sub-group is less likely to respond to topical
clindamycin therapy in terms of a return to normal
vaginal flora and outcome of pregnancy. The sub-
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group comprises mainly women with grade II vagi-
nal flora who can easily be identified by examina-
tion of a Gram-stained smear of vaginal secretion
early in pregnancy. However, a further group of
women whose Gram-stained smears are graded as
III, but who are less likely to be carrying anaerobic
Gram-negative rods than other women who have
grade III smears, also may be less likely to respond
to clindamycin. More work is needed to determine
what factors (microbiological or otherwise) may be
determining abnormal outcome in this sub-group.
Data from the revertant group suggest that dam-
age from abnormal flora may have occurred early in
pregnancy and thus earlier diagnosis and treatment
may demonstrate a significant reduction in abnor-
mal outcome of pregnancy. We would thus recom-
mend that screening for abnormal flora should be
carried out as soon as pregnancy is diagnosed or
even offered as a pre-conception screen.
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